Hedgehog通路抑制剂索尼德吉治疗激素难治性慢性移植物抗宿主病的1期研究
该1期试验采用3+3设计,评估索尼德吉(Smoothened选择性拮抗剂)治疗激素难治性慢性移植物抗宿主病,设200、400、600 mg/日三个剂量水平,最多12个28天周期。17例患者入组,仅观察到1例剂量限制性毒性(队列2,3级肌酸磷酸激酶升高)。8例(47%)在皮肤或硬皮病样病变获部分缓解,6例无缓解,3例不可评估;患者整体报告生活质量恶化,非缓解者更严重。
要点
- 索尼德吉设200、400、600 mg/日三个剂量水平,最多12个28天周期,17例入组。
- 仅1例剂量限制性毒性:队列2发生3级肌酸磷酸激酶升高。
- 8例(47%)皮肤或硬皮病样病变部分缓解,6例无缓解,3例不可评估。
核心结论
- 作者认为Hedgehog信号抑制因与临床缓解及免疫组化改变相关,值得在cGVHD患者中进一步研究。
研究设计与样本
- 1期试验采用3+3设计,索尼德吉给药最多12个周期、每周期28天,剂量为200 mg/日(剂量水平1)、400 mg/日(剂量水平2)、600 mg/日(剂量水平3),共17例患者入组。
主要发现
- 完成周期数中位为6(范围0-12)。
- 仅观察到1例剂量限制性毒性(队列2,3级肌酸磷酸激酶升高)。
- 皮肤活检免疫组化显示索尼德吉治疗后Hedgehog信号通路分子蛋白表达降低。
- 8例(47%)在皮肤或硬皮病样病变获部分缓解,6例无缓解,3例不可评估。
- 临床缓解由治疗医生评估而非美国国立卫生研究院标准;患者整体报告生活质量恶化,临床非缓解者更严重。
关键数值与推荐
- 因累积毒性负担(非归因于索尼德吉)及患者决定停药而提前终止入组。
- 试验注册号为NCT02086513。
临床怎么用
- 原文未据此给出推荐。
局限性
- 临床缓解由治疗医生评估而非美国国立卫生研究院标准。
- 因累积毒性负担(非归因于索尼德吉)及患者决定停药而提前终止入组。
- 作者认为Hedgehog信号抑制值得在cGVHD患者中进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hedgehog signaling plays a key role in tissue fibrosis, the pathological hallmark of chronic graft-versus-host disease (cGVHD). We conducted a phase 1 trial of sonidegib, a selective antagonist of the hedgehog coreceptor Smoothened, for the treatment of steroid-refractory cGVHD. After a 3+3 study design, sonidegib was administered for up to 12 cycles of 28 days each, using 3 doses: 200 mg/day (dose level 1), 400 mg/day (dose level 2), and 600 mg/day (dose level 3). Seventeen patients were enrolled. The median number of cycles completed was 6 (range, 0-12). There was only 1 dose-limiting toxicity (cohort 2, grade 3 creatine phosphokinase increase) observed. Immunohistochemical evaluation of skin biopsies revealed decreased protein expression of hedgehog signaling pathway molecules with sonidegib therapy. Clinically, 8 patients (47%) had a partial response in skin or sclerodermatous disease, 6 patients had no response, and 3 were not evaluable. Clinical responses were assessed by treating physicians and not by National Institutes of Health criteria. Overall, patients reported worsening of quality of life, which was more severe in clinical nonresponders. Accrual was terminated early as a result of the cumulative toxicity burden not attributed to sonidegib and patient decisions to stop taking sonidegib. We believe hedgehog signaling inhibition warrants further investigation in patients with cGVHD because of the association with clinical responses and immunohistochemical changes. This trial was registered at www.clinicaltrials.gov as #NCT02086513.
引用
- DeFilipp Z, Nazarian RM, El-Jawahri A, et al. Phase 1 study of the Hedgehog pathway inhibitor sonidegib for steroid-refractory chronic graft-versus-host disease. Blood Adv. 2017. PMID: 29296838. doi:10.1182/bloodadvances.2017011239
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。